|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Suppl 1. The overlap propensity score weighted characteristics of mechanically ventilated hospitalizations** | | | | | |
| **with COVID-19 and influenza** |  |  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **COVID-19a** | **Influenza** |  |
|  | **n = 19,659** | **n = 2,536** |  |
| **Age, years (%)** |  |  |  |
| 18-44 | 10.8 | 10.8 |  |
| 45-64 | 31.1 | 31.1 |  |
| ≥ 65 | 58.1 | 58.1 |  |
| **Gender (%)** |  |  |  |
| Female | 47.0 | 47.0 |  |
| Male | 42.6 | 42.6 |  |
| Suppressedb | 10.4 | 10.4 |  |
| **Race/ethnicity (%)** |  |  |  |
| White | 53.2 | 53.2 |  |
| Hispanic | 21.8 | 21.8 |  |
| Black | 17.9 | 17.9 |  |
| Other | 7.0 | 7.0 |  |
| **Health insurance (%)** |  |  |  |
| Private | 41.7 | 41.7 |  |
| Medicare | 36.5 | 36.5 |  |
| Medicaid | 8.6 | 8.6 |  |
| Uninsured | 10.1 | 10.1 |  |
| Other | 2.5 | 2.5 |  |
| Missing | 0.5 | 0.5 |  |
| **Deyo comorbidity indexc** | 2.55 | 2.55 |  |
| **Comorbid conditions (%)** |  |  |  |
| Diabetes | 40.6 | 40.6 |  |
| Liver disease | 5.7 | 5.7 |  |
| Malignancy | 6.6 | 6.6 |  |
| Congestive heart failure | 47.8 | 47.8 |  |
| Chronic lung disease | 50.1 | 50.1 |  |
| Myocardial infarction | 18.4 | 18.4 |  |
| Peripheral vascular disease | 4.1 | 4.1 |  |
| Dementia | 7.3 | 7.3 |  |
| Peptic ulcer disease | 1.5 | 1.5 |  |
| Hemiplegia/paraplegia | 2.1 | 2.1 |  |
| HIVd | 0.8 | 0.8 |  |
| Cerebrovascular disease | 7.4 | 7.4 |  |
| Chronic renal disease | 25.3 | 25.3 |  |
| Rhumatological disease | 4.1 | 4.1 |  |
| Obesity | 30.8 | 30.8 |  |
| Tobacco use | 17.4 | 17.4 |  |
| Alcohol use | 4.8 | 4.8 |  |
| Substance use | 5.9 | 5.9 |  |
| **Number of organ dysfunctionsc** | 2.26 | 2.26 |  |
| **Hemodialysis (%)** | 5.2 | 5.2 |  |
| **ECMOe (%)** | 0.1 | 0.1 |  |
| **Do-not-resuscitatef (%)** | 22.6 | 22.6 |  |
| **Palliative care (%)** | 14.9 | 14.9 |  |
| **Teaching hospital (%)** | 26.4 | 26.4 |  |
| **Hospital admission period (%)** |  |  |  |
| Fourth quarter 2021 | 8.3 | 8.3 |  |
| First quarter 2022 | 18.1 | 18.1 |  |
| Second quarter 2022 | 10.6 | 10.6 |  |
| Third quarter 2022 | 5.9 | 5.9 |  |
| Fourth quarter 2022 | 34.1 | 34.1 |  |
| First quarter 2023 | 23.0 | 23.0 |  |
| a COVID-19: coronavirus disease 2019 | |  |  |
| b The State of Texas suppresses gender data of hospitalizations with human immunodeficiency virus infection, | | | |
| alcohol use, and substance use |  |  |  |
| c mean value |  |  |  |
| d HIV: human immunodeficiency virus | |  |  |
| e ECMO: extracorporeal membrane oxygenation | |  |  |
| f Do-not-resuscitate: a do-not-resuscitate state | |  |  |